Background: About 90% of patients with hidradenitis suppurativa (HS) are smokers. A crucial eliciting role of smoking appears to be certain. In order to increase the awareness of this avoidable major cause of the disease and to facilitate the recognition of incipient disorder, we propose the more specific term ‘smoker’s boils’ for HS lesions of patients who are smokers. Method: Clinical pictures of early lesions are presented. For the exceptional cases occurring in nonsmokers, the traditional name HS, representing an umbrella term, is adequate. Result/Conclusion: The renaming of HS as smoker’s boils has the practical advantage that a correct diagnosis can be made at an incipient stage of the disorder. If patients stop smoking at such an early stage of HS, they most likely have a chance that this devastating disease will not progress.

1.
Jansen I, Altmeyer P, Plewig G: Acne inversa (alias hidradenitis suppurativa). J Eur Acad Dermatol Venereol 2001;15:532–540.
2.
Wiseman MC: Hidradenitis suppurativa: a review. Dermatol Ther 2004;17:50–54.
3.
Jemec GBE, Revuz J, Leyden JJ: Hidradenitis Suppurativa. Berlin, Springer, 2006.
4.
Maclean GM, Coleman DJ: Three fatal cases of squamous cell carcinoma arising in chronic perineal hidradenitis suppurativa. Ann R Coll Surg Engl 2007;89:709–712.
5.
von der Werth JM, Williams HC, Raeburn JA: The clinical genetics of hidradenitis suppurativa revisited. Br J Dermatol 2000;142:947–953.
6.
Breitkopf C, Bockhorst J, Lippold A, Ernst K, Hundeiker M: Pyodermia fistulans sinifica (Acne inversa) und Rauchgewohnheiten. Z Hautkr 1995;70:332–334.
7.
König A, Lehmann C, Rompel R, Happle R: Cigarette smoking as a triggering factor of hidradenitis suppurativa. Dermatology 1999;198:261–264.
8.
Kurzen H, Schönfelder-Funcke S, Hartschuh W: Surgical treatment of acne inversa at the University of Heidelberg. Coloproctology 2000;22:76–80.
9.
Kurzen H, Kurokawa I, Jemec GB, Emtestam L, Sellheyer K, Giamarellos-Bourboulis EJ, Nagy I, Bechara FG, Sartorius K, Lapins J, Krahl D, Altmeyer P, Revuz J, Zouboulis CC: What causes hidradenitis suppurativa? Exp Dermatol 2008;17:455–456, discussion 457–472.
10.
Sartorius K, Emtestam L, Jemec GB, Lapins J: Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity. Br J Dermatol 2009;161:831–839.
11.
Matusiak L, Bieniek A, Szepietowski JC: Hidradenitis suppurativa and associated factors: still unsolved problems. J Am Acad Dermatol 2009;61:362–365.
12.
Boer J, Jemec GB: Resorcinol peels as a possible self-treatment of painful nodules in hidradenitis suppurativa. Clin Exp Dermatol 2010;35:36–40.
13.
Cesko E, Korber A, Dissemond J: Smoking and obesity are associated factors in acne inversa: results of a retrospective investigation in 100 patients. Eur J Dermatol 2009;19:490–493.
14.
Haussler A, Paul E, Schultz ES: Acne inversa: investigation on parameters influencing outbreak and course of the disease (in German). Aktuelle Derm 2010;36:255–258.
15.
Balabanova S, Bühler G, Schneider E, Boschek HJ, Schneitler H: Nicotine excretion by the apocrine and eccrine sweat in smokers and passive smokers (in German). Hautarzt 1992;43:73–76.
16.
Balabanova S, Krupienski M: Detection of nicotine in eccrine sweat after stimulation of sweat glands during nicotine withdrawal (in German). Hautarzt 1995;46:255–258.
17.
Fardet L, Dupuy A, Kerob D, Levy A, Allez M, Begon E, Bachelez H, Morel P, Lebbé C: Infliximab for severe hidradenitis suppurativa: transient clinical efficacy in 7 consecutive patients. J Am Acad Dermatol 2007;56:624–628.
18.
Lam J, Krakowski AC, Friedlander SF: Hidradenitis suppurativa (acne inversa): management of a recalcitrant disease. Pediatr Dermatol 2007;24:465–473.
19.
Krbec AC: Current understanding and management of hidradenitis suppurativa. J Am Acad Nurse Pract 2007;19:228–234.
20.
Wolkenstein P, Loundou A, Barrau K, Auquier P, Revuz J: Quality of life impairment in hidradenitis suppurativa: a study of 61 cases. J Am Acad Dermatol 2007;56:621–623.
21.
von Laffert M, Helmbold P, Wohlrab J, Fiedler E, Stadie V, Marsch WC: Hidradenitis suppurativa (acne inversa): early inflammatory events at terminal follicles and at interfollicular epidermis. Exp Dermatol 2010;19:533–537.
22.
Reddick CL, Singh MN, Chalmers RJ: Successful treatment of superficial pyoderma gangrenosum associated with hidradenitis suppurativa with adalimumab. Dermatol Online J 2010;16:15.
23.
Adams DR, Yankura JA, Fogelberg AC, Anderson BE: Treatment of hidradenitis suppurativa with etanercept injection. Arch Dermatol 2010;146:501–504.
24.
Poli F, Wolkenstein P, Revuz J: Back and face involvement in hidradenitis suppurativa. Dermatology 2010;221:137–141.
25.
Brocard A, Knol AC, Khammari A, Dreno B: Hidradenitis suppurativa and zinc: a new therapeutic approach – a pilot study. Dermatology 2007;214:325–327.
26.
Lasocki A, Sinclair R, Foley P, Saunders H: Hidradenitis suppurativa responding to treatment with infliximab. Australas J Dermatol 2010;51:186–190.
27.
Shuster S: A lesson to be learned from Karl Marx: smoking triggers hidradenitis suppurativa (author reply). Br J Dermatol 2008;159:256–257.
28.
Revuz JE, Canoui-Poitrine F, Wolkenstein P, Viallette C, Gabison G, Pouget F, Poli F, Faye O, Roujeau JC, Bonnelye G, Grob JJ, Bastuji-Garin S: Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. J Am Acad Dermatol 2008;59:596–601.
32.
Fitzsimmons JS, Guilbert PR, Fitzsimmons EM: Evidence of genetic factors in hidradenitis suppurativa. Br J Dermatol 1985;113:1–8.
33.
Revuz J: Medical treatments of hidradenitis suppurativa: a new paradigm. Dermatology 2007;215:95–96.
34.
Smith HS, Chao JD, Teitelbaum J: Painful hidradenitis suppurativa. Clin J Pain 2010;26:435–444.
35.
Matusiak L, Bieniek A, Szepietowski JC: Hidradenitis suppurativa markedly decreases quality of life and professional activity. J Am Acad Dermatol 2010;62:706–708.
36.
Buimer MG, Wobbes T, Klinkenbijl JH: Hidradenitis suppurativa. Br J Surg 2009;96:350–360.
37.
Lookingbill DP: Yield from a complete skin examination: findings in 1,157 new dermatology patients. J Am Acad Dermatol 1988;18:31–37.
38.
Jemec GB, Heidenheim M, Nielsen NH: The prevalence of hidradenitis suppurativa and its potential precursor lesions. J Am Acad Dermatol 1996;35:191–194.
39.
Skírnisson K, Aldhoun JA, Kolárová L: A review on swimmer’s itch and the occurrence of bird schistosomes in Iceland. J Helminthol 2009;83:165–171.
40.
Stracher M, Posner MA: Boxer’s knuckle. Tech Hand Up Extrem Surg 2002;6:196–199.
41.
Heim D: The skier’s thumb. Acta Orthop Belg 1999;65:440–446.
42.
Arroll B, Edwards A: Runner’s knee: what is it and what helps? Br J Gen Pract 1999;49:92–93.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.